PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Epoetin→

Epoetin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
113427-24-0
Molecular formula
C809H1301N229O240S5
Molecular weight
~30400 g/mol
Drug class
Erythropoiesis-stimulating agent (ESA)recombinant human erythropoietin biologic
Mechanism of action
Binds erythropoietin receptors on erythroid progenitor cells in bone marrow, stimulating survival, proliferation and differentiation of erythroid precursors and increasing red blood cell production.
Indications / reported uses
  • Treatment of anaemia associated with chronic kidney disease in selected patients
  • Treatment of zidovudine-associated anaemia in selected patients with HIV infection
  • Treatment of anaemia in selected patients with non-myeloid malignancies receiving myelosuppressive chemotherapy
  • Reduction of allogeneic red blood cell transfusion requirements in selected patients undergoing elective, non-cardiac, non-vascular surgery; indications are specific to the epoetin product label

Sources: US DailyMed — EPOGEN (epoetin alfa) · US DailyMed — PROCRIT (epoetin alfa) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Epoetin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Epoetin Permitted Daily Exposure (PDE) report (the Epoetin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Epoetin Occupational Exposure Limit (OEL) report (the Epoetin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.